Financial Performance - The company's operating revenue for Q1 2024 was ¥189,493,463.31, representing a 3.44% increase compared to ¥183,185,038.02 in the same period last year[5] - Net profit attributable to shareholders reached ¥18,284,352.36, a significant increase of 947.75% from a loss of ¥2,156,812.13 in the previous year[5] - The net cash flow from operating activities was ¥35,485,717.14, marking a 640.55% increase from a negative cash flow of ¥6,564,702.62 in the same period last year[5] - Basic and diluted earnings per share were both ¥0.0757, compared to a loss of ¥0.0089 per share in the previous year, reflecting a 950.56% improvement[5] - The company's net profit for Q1 2024 reached CNY 24,945,683.88, a significant increase compared to CNY 2,981,088.59 in Q1 2023, representing a growth of approximately 736%[26] - Operating profit for Q1 2024 was CNY 18,435,645.08, compared to a loss of CNY 2,612,624.93 in the same period last year, indicating a turnaround in operational performance[26] - The total comprehensive income for Q1 2024 was CNY 24,945,683.88, compared to CNY 2,981,088.59 in the same quarter last year, indicating a substantial improvement[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,476,233,754.13, an increase of 3.01% from ¥1,433,075,413.12 at the end of the previous year[5] - Total liabilities increased to CNY 672,856,013.43 from CNY 654,643,356.30, indicating an increase of about 2.3%[24] - The total equity attributable to shareholders of the parent company improved to CNY 618,416,875.06 from CNY 600,132,522.70, marking an increase of approximately 3.0%[24] Research and Development - The company's R&D expenses for the period were ¥12,048,200, representing a 34.95% increase compared to the same period last year[8] - Research and development expenses increased to CNY 12,048,160.13 in Q1 2024, up from CNY 8,927,664.99 in Q1 2023, reflecting a year-over-year growth of approximately 35%[26] - The company plans to continue investing in R&D and market expansion to drive future growth, although specific new products or technologies were not detailed in the report[31] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,531[12] - The largest shareholder, Weng Zhangguo, holds 6.53% of shares, totaling 15,772,409 shares[12] - Shareholder Zhao Qun holds 5.55% of shares, totaling 13,401,892 shares, with 10,051,419 shares under lock-up[12] - The total number of restricted shares at the end of the period is 16,596,968 shares, all under executive lock-up[15] - The top ten shareholders include both domestic and foreign individuals, with varying percentages of ownership[12] - The company has not reported any changes in the lending or borrowing of shares among the top ten shareholders[13] - The company has not disclosed any related party relationships among the top ten shareholders[12] Cash Flow and Financing - The net cash flow from financing activities was ¥11,056,300, an increase of 211.76% compared to the previous year[10] - Cash and cash equivalents at the end of Q1 2024 stood at CNY 131,907,074.24, down from CNY 341,918,562.95 at the end of Q1 2023[30] - The company incurred financial expenses of CNY 3,743,632.23 in Q1 2024, a decrease from CNY 11,252,129.49 in Q1 2023, showing a reduction of approximately 67%[26] Operational Highlights - The company reported a significant increase in non-operating income, with government subsidies amounting to ¥2,409,636.37, contributing to overall profitability[6] - Total revenue from sales of goods and services in Q1 2024 was CNY 197,655,753.57, compared to CNY 184,433,813.87 in Q1 2023, marking an increase of about 7%[30] - The total operating costs for the current period amount to CNY 176,063,821.72, down from CNY 185,981,096.81 in the previous period, indicating a decrease of about 5.0%[25] Corporate Governance - The company plans to issue new shares to specific investors as part of its capital raising strategy, as approved in the board meeting[19] - The company has revised its governance structure and related policies to comply with the latest regulations, enhancing operational management[19] Other Information - The company provided a joint guarantee for a loan of RMB 40 million for Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. with a term of 2 years[16] - The subsidiary Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. has been re-certified as a high-tech enterprise[17] - The company has returned RMB 50 million of temporarily used funds to its special fundraising account within 12 months[17] - Accounts receivable decreased to CNY 99,343,672.36 from CNY 107,802,272.28, representing a decline of approximately 7.5%[22] - Inventory increased to CNY 127,561,035.80 from CNY 120,831,093.39, showing an increase of about 5.7%[23]

证券代码：300254 证券简称：仟源医药 公告编号：2024-036 二、董事会会议审议情况 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以投票表决方 式审议通过了如下议案： 山西仟源医药集团股份有限公司 第五届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）于 2024 年 4 月 9 日以 邮件方式发出第五届董事会第十五次会议通知及议案，2024 年 4 月 12 日以通讯表 决的方式召开本次会议。本次会议由董事长黄乐群先生主持，应出席董事 8 名， 实际出席董事 8 名。出席会议人员对本次会议的召集、召开方式无异议。本次会 议的召集、召开符合《公司法》《公司章程》和《董事会议事规则》的有关规定。 表决结果：同意 8 票；反对 0 票；弃权 0 票。 1、审议通过《关于公司<2024 年第一季度报告>的议案》 2、审议通过《关于公司前次募集资金使用情况报告的议案》 经审议，与会董事认为：公司《2024 年第一季度报告》所载资料内容符合法律、 行 ...

证券代码：300254 证券简称：仟源医药 公告编号：2024-038 山西仟源医药集团股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）第五届监事会第十一次 会议（以下简称"本次会议"）于 2024 年 4 月 12 日（下午）召开。本次会议由监 事会主席朱海波先生主持，应到监事 3 名，实到监事 3 名。董事会秘书、证券事务 代表列席本次会议，出席会议人员对本次会议的召集、召开方式无异议。本次会议 的召集、召开符合《公司法》法律、法规等规范性文件和《公司章程》的有关规定。 二、监事会会议审议情况 出席本次会议的全体监事对本次会议的议案进行了认真审议，并以投票表决方 式审议通过了如下议案： 1、审议通过《关于公司<2024 年第一季度报告>的议案》 经审议，监事会认为：公司《2024 年第一季度报告》所载资料内容符合法律、 行政法规、中国证监会和深圳证券交易所的相关规定，报告内容真实、准确、完整， 不存在任何虚假记载、误导性陈述或者重大遗漏。 具体 ...

证券代码：300254 证券简称：仟源医药 公告编号：2024-039 山西仟源医药集团股份有限公司 前次募集资金使用情况报告 (截至2024年3月31日止) 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《监管规则适用指引——发行类第7号》的相关 规定，本公司将截至2024年3月31日止前次募集资金使用情况报告如下： 一、 前次募集资金基本情况 （一）2020 年度向特定对象发行股票募集资金 经中国证券监督管理委员会《关于同意山西仟源医药集团股份有限公司向特 定对象发行股票注册的批复》（证监许可 (2020) 2273 号）批复，本公司以简易程 序向 2 名特定对象发行人民币普通股（A 股）19,662,921 股，每股发行价格 7.12 元，募集资金总额 139,999,997.52 元，扣除发行费用人民币 6,419,432.89 元（不含 增值税），募集资金净额为人民币 133,580,564.63 元。本公司于 2020 年 9 月 29 日收到扣除承销商承销及保荐费用 5,000,000.00 元后的募集资金 134,9 ...

证券代码：300254 证券简称：仟源医药 公告编号：2024-037 山西仟源医药集团股份有限公司 关于召开2024年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 经山西仟源医药集团股份有限公司（以下简称"公司"）第五届董事会第十 五次会议审议，公司决定于 2024 年 4 月 29 日（星期一）召开公司 2024 年第二 次临时股东大会。现将会议有关事项通知如下： 一、召开会议基本情况 1、股东大会届次：2024 年第二次临时股东大会 2、股东大会的召集人：公司第五届董事会 3、会议召开的合法性及合规性：董事会召开本次股东大会会议符合《公司 法》、《证券法》、《深圳证券交易所创业板股票上市规则》、《上市公司股东 大会规则》等有关法律、法规、规则以及《公司章程》的规定。 4、会议召开日期和时间： 现场会议召开时间：2024 年 4 月 29 日（星期一）下午 2:30 网络投票时间为： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为 2024 年 4 月 29 日 9:15-9：25，9：30-11:30 和 13:00 ...

特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 1、会议召开时间： （1）现场会议召开时间为：2024年4月9日（星期二）下午2:30 证券代码：300254 证券简称：仟源医药 公告编号：2024-034 山 西 仟 源 医 药集 团 股 份有 限 公 司 2 023年年 度 股 东大 会 决 议公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （2）网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体 时间为 2024 年 4 月 9 日 9:15-9：25，9：30-11:30 和 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为 2024 年 4 月 9 日上午 9:15 至下午 15:00 期间的任意时间。 2、现场会议召开地点：上海市徐汇区龙耀路175号星扬西岸3605室 3、会议方式：本次股东大会采取现场投票和网络投票相结合的方式 4、召集人：公司第五届董事会 5、主持人：副董事长钟海荣先生 6、会议出席情况： （1）股东出席的 ...

国浩律师（上海）事务所 关于 山西仟源医药集团股份有限公司 2023 年年度股东大会 之 法律意见书 上海市北京西路 968 号嘉地中心 23-25 层 邮编：200041 23-25/F, Garden Square, 968 West Beijing Road, Shanghai 200041, China 电话/Tel: (+86)(21) 5234 1668 传真/Fax: (+86)(21) 5243 3320 网址/Website: http://www.grandall.com.cn 二〇二四年四月 国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于山西仟源医药集团股份有限公司 2023 年年度股东大会 之 法律意见书 致：山西仟源医药集团股份有限公司 本所律师依据本法律意见书出具之日以前已发生或存在的事实和我国现行 法律、法规和中国证监会的有关规定发表法律意见，并声明如下： （一）本所律师是依据《公司法》《证券法》《股东大会规则》等相关法律、 法规及规范性文件的规定及本法律意见书出具之日以前已发生或存在的相关事 实，就公司本次召开股东大会相关事宜发表法律意见。 （二）本所律师已严 ...

证券代码：300254 证券简称：仟源医药 公告编号：2024-033 山西仟源医药集团股份有限公司 关于召开2023年年度股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）于 2024 年 3 月 19 日在 巨潮资讯网（www.cninfo.com.cn）发布了《关于召开 2023 年年度股东大会的通知》（公 告编号：2024-031）。公司定于 2024 年 4 月 9 日（星期二）以现场表决与网络投 票相结合的方式召开 2023 年年度股东大会。现将会议有关事项再次提示如下： 一、召开会议基本情况 2、股东大会的召集人：公司第五届董事会 3、会议召开的合法性及合规性：董事会召开本次股东大会会议符合《公司 法》、《证券法》、《深圳证券交易所创业板股票上市规则》、《上市公司股东 大会规则》等有关法律、法规、规则以及《公司章程》的规定。 4、会议召开日期和时间： 现场会议召开时间：2024 年 4 月 9 日（星期二）下午 2:30 网络投票时间为： （1）通过深圳证券交易所交易系统进行网络 ...

Financial Performance - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. reported a revenue of 1.2 billion RMB for 2023, representing a year-on-year increase of 15%[22]. - The company's operating revenue for 2023 was ¥799,305,103.37, a decrease of 3.58% compared to ¥828,997,054.54 in 2022[29]. - Net profit attributable to shareholders for 2023 was ¥25,195,587.09, a significant increase of 121.26% from a loss of ¥91,437,557.03 in 2022[28]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥19,007,536.20, an improvement of 84.08% from -¥132,680,529.83 in 2022[28]. - The net cash flow from operating activities decreased by 49.50% to ¥37,814,367.70 in 2023 from ¥74,876,116.40 in 2022[28]. - Basic and diluted earnings per share for 2023 were both ¥0.1043, a turnaround from -¥0.5002 in 2022, reflecting a 120.86% increase[28]. - Total assets at the end of 2023 were ¥1,433,075,413.12, down 9.55% from ¥1,584,324,080.00 at the end of 2022[28]. - Net assets attributable to shareholders at the end of 2023 were ¥600,132,522.70, an increase of 4.38% from ¥574,921,302.39 at the end of 2022[28]. - The company reported quarterly revenues of ¥183,185,038.02, ¥182,396,082.68, ¥206,358,063.45, and ¥227,365,919.22 for Q1 to Q4 respectively in 2023[31]. Investment and R&D - The company plans to invest 200 million RMB in R&D for new drug development in the next fiscal year, focusing on innovative therapies and generics[22]. - The company is exploring strategic acquisitions to enhance its market presence and expand its product portfolio in the next two years[22]. - A new line of anti-infection drugs is set to launch in Q2 2024, expected to contribute significantly to revenue growth[22]. - The company has made progress in several drug development projects, including obtaining a drug registration certificate for the varenicline project in February 2023[45]. - The company has obtained two new drug registration certificates for varenicline from its subsidiary in the reporting period[48]. - The company plans to invest 4,050 million CNY in ongoing drug development projects after reallocating funds from terminated projects[93]. - The company has several new product development projects, including the development of new drugs and obtaining production approvals, aimed at expanding the product line and enhancing competitiveness[71]. Market and Industry Outlook - The company has outlined a future outlook with a projected revenue growth of 10-15% for 2024, driven by market expansion and new product launches[22]. - The pharmaceutical industry in China experienced a revenue decline of 3.7% year-on-year, totaling 25,205.7 billion yuan in 2023[36]. - The total profit for the pharmaceutical manufacturing industry decreased by 15.1% year-on-year, amounting to 3,473 billion yuan in 2023[36]. - The company is positioned in a rapidly evolving pharmaceutical sector, influenced by multiple regulatory policies and reforms aimed at enhancing drug procurement and pricing mechanisms[37]. - The government has issued over 100 policies to support the development of the pharmaceutical industry as of December 2023[37]. - The company anticipates further improvements in drug approval processes and innovation due to ongoing regulatory reforms[36]. - The healthcare reform initiatives aim to alleviate the challenges of accessing affordable medical care for the public[38]. Corporate Governance and Management - The company completed the election of the fifth board of directors and supervisory board on February 16, 2023, ensuring compliance with legal requirements[116]. - The board of directors consists of 8 members, including 4 independent directors, enhancing governance structure and decision-making efficiency[116]. - The company has established a comprehensive and independent financial management system, ensuring financial independence and decision-making autonomy[121]. - The company emphasizes transparency and timely information disclosure, adhering to legal requirements and ensuring equal access to information for all shareholders[118]. - The company has implemented a performance evaluation and incentive mechanism for employees, fostering a fair and efficient work environment[119]. - The company has increased the number of independent directors on the board to enhance governance and oversight[116]. - The company has established various communication channels with investors to ensure their rights and interests are protected[118]. Risk Management - The company has identified potential risks in production and regulatory compliance, with strategies in place to mitigate these risks[5]. - The company faces risks from industry policy changes, which could impact drug sales and competition, necessitating a focus on high-end drug development[109]. - There is a significant risk of drug price reductions due to national healthcare cost control measures, which could compress profit margins[109]. - The company is at risk of key products exiting the National Medical Insurance Directory, which could adversely affect revenue[109]. - Rising raw material costs pose a risk, prompting the company to implement lean production practices to improve efficiency and reduce costs[111]. Environmental Responsibility - Shanxi Qianyuan Pharmaceutical has complied with all relevant environmental protection laws and standards during its operations[163]. - The company holds a valid pollution discharge permit, effective until March 3, 2028[164]. - The total annual discharge of wastewater pollutants was reported at 4 tons, with no exceedances of discharge limits[165]. - The company has implemented measures to ensure that emissions of key pollutants are within regulatory standards[165]. - The company invested CNY 2.5934 million in environmental governance and protection in 2023[168]. - The wastewater treatment capacity is 150 m³ per day, utilizing an "A/O" treatment process[167]. - The company has installed online automatic monitoring devices for chemical oxygen demand, ammonia nitrogen, flow, and pH at the wastewater discharge outlet[168]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,234, with 479 in the parent company and 755 in major subsidiaries[148]. - The company has implemented a comprehensive training program to enhance employee skills and management capabilities, contributing to stable team development[150]. - The company adheres to labor laws and provides competitive compensation packages to attract and retain talent[149]. - The educational background of employees includes 46 with postgraduate degrees, 376 with bachelor's degrees, and 812 with college diplomas or below[148]. Shareholder Returns - Shanxi Qianyuan will not distribute cash dividends or issue bonus shares for the fiscal year 2023, opting to reinvest profits into business growth[7]. - The profit distribution plan for 2023 also indicates no cash dividends, stock bonuses, or capital reserve transfers, pending approval from the annual shareholders' meeting[154]. - The company has a three-year shareholder return plan for 2024-2026[123].

证券代码：300254 证券简称：仟源医药 公告编号：2024-029 山西仟源医药集团股份有限公司 关于对外投资设立合资公司的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本次对外投资事项不构成关联交易，也不构成《上市公司重大资产重组管理 办法》规定的重大资产重组。 二、交易对手的基本情况 交易对方：北京亿药科技有限公司 统一社会信用代码：91110114MA01DPPC4Q 一、交易概述 1、本次对外投资基本情况 2024 年 3 月 16 日，山西仟源医药集团股份有限公司（以下简称"公司"或 "仟源医药"）与北京亿药科技有限公司（以下简称"亿药科技"）签署《设立 合资公司合同》，未来双方将聚焦基于 AI 制药技术前提下创新药物的研发、产业 化和商业化的合作。 合资公司注册资本拟定为人民币 12,000 万元，公司出资 7,200 万元，其中， 以货币形式认缴出资人民币 3,600 万元，以设备、技术等非货币形式出资人民币 3,600 万元，公司占合资公司 60%股权；亿药科技以仟源医药选定的两条管线涉 及的专利、技术秘密等非货币形式出资人民币 4 ...